	Item No	Recommendation
Title and abstract	1 <b>(</b> <i>a</i> ) Indi	cate the study's design with a commonly used term in the title or the abstract
	(b) Prov	vide in the abstract an informative and balanced summary of what was done
	and wh	at was found
Introduction		
Background/rationale	2 Explain	the scientific background and rationale for the investigation being reported
Objectives	3 State sp	pecific objectives, including any prespecified hypotheses
Methods	-	
Study design	4 Present	key elements of study design early in the paper
Setting	•	be the setting, locations, and relevant dates, including periods of recruitment,
	exposu	re, follow-up, and data collection
Participants	6 <b>V</b> (a) Coh	nort study—Give the eligibility criteria, and the sources and methods of
	selectio	on of participants. Describe methods of follow-up
	Case-co	ontrol study—Give the eligibility criteria, and the sources and methods of
	case asc	certainment and control selection. Give the rationale for the choice of cases
	and cor	ntrols
	Cross-s	rectional study—Give the eligibility criteria, and the sources and methods of
	selectio	on of participants
	(b) Coh	nort study—For matched studies, give matching criteria and number of
	exposed	d and unexposed
	<b>√</b> case-co	ontrol study—For matched studies, give matching criteria and the number of
	controls	s per case
Variables	7 Clearly	define all outcomes, exposures, predictors, potential confounders, and effect
	modifie	ers. Give diagnostic criteria, if applicable
Data sources/	8* For each	ch variable of interest, give sources of data and details of methods of
measurement	assessm	nent (measurement). Describe comparability of assessment methods if there
	is more	than one group
Bias	<sub>9</sub> n/a <sub>Describ</sub>	be any efforts to address potential sources of bias
Study size	10 n/ <b>E</b> xplain	how the study size was arrived at
Quantitative variables	11 n/aExplain	how quantitative variables were handled in the analyses. If applicable,
	describe	e which groupings were chosen and why
Statistical methods	12 (a) Des	cribe all statistical methods, including those used to control for confounding
	(b) Des	cribe any methods used to examine subgroups and interactions
	(c) Exp	lain how missing data were addressed
	(d) Coh	nort study—If applicable, explain how loss to follow-up was addressed
		ontrol study—If applicable, explain how matching of cases and controls was
	address	
		sectional study—If applicable, describe analytical methods taking account of
		ng strategy
	·	cribe any sensitivity analyses
Continued on next page	<u> </u>	• • •

Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed
		(b) Give reasons for non-participation at each stage
		(c) Consider use of a flow diagram
Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information
data		on exposures and potential confounders
		(b) Indicate number of participants with missing data for each variable of interest
		Cohort study—Summarise follow-up time (eg, average and total amount)
Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over time
		Case-control study—Report numbers in each exposure category, or summary measures of
		exposure
		Cross-sectional study—Report numbers of outcome events or summary measures
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their
		precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and
		why they were included
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful
		time period
Other analyses	17 <b>n</b>	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity
		analyses
Discussion		
Key results	18	Summarise key results with reference to study objectives
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision.
		Discuss both direction and magnitude of any potential bias
Interpretation	-20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
		of analyses, results from similar studies, and other relevant evidence
Generalisability	21	Discuss the generalisability (external validity) of the study results
Other informat	ion	
	22	Give the source of funding and the role of the funders for the present study and, if applicable,
	n/a	for the original study on which the present article is based

<sup>\*</sup>Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.